Species-level identification of Achromobacter is difficult and isolates are frequently misidentified [7] . At present, the genus comprises 19 validly named species [8] [9] [10] and the clinical importance of different Achromobacter sp. has not been comprehensively studied. The aim of this study was to evaluate the species distribution and putative transmission of Achromobacter sp. isolates from patients affiliated with the CF centre at Aarhus University Hospital, Denmark, during 2003-2014. Patients visit the CF centre on a monthly basis and respiratory secretions for culture are secured by laryngeal aspiration if patients do not produce sputum. Chronic colonisation was defined as Achromobacter in more than 50 % of sputum samples collected during the last 12 months, with a minimum of four sputum samples during that period. Patients were registered as chronically infected from the date of the first sample in the period. Identification to genus was performed by MALDI-TOF analysis (Biotyper, Bruker), and isolates were stored in semi-liquid agar at ambient temperature. nrdA gene sequencing was performed as previously described [11] on one selected isolate from each patient. Longitudinal analysis of multiple isolates has shown that each patient persistently carries isolates of a single genotype [3, 6] . Therefore only one isolate per patient was included. Species-level identification was performed by comparing nrdA gene fragments with deposited sequences in the MLST database (http://pubmlst.org/achromobacter/) [12] . PFGE was performed using the restriction enzyme XbaI as previously described [13] , and patterns were interpreted according to established criteria [14] . Association of chronic infection with the three most prevalent species in our CF population was evaluated using Fisher's exact test, implemented in R 3.2.0 (www.R-project.org).
From 2003 through 2014, 43 out of a total of 225 (19.3 %) CF patients affiliated with the CF centre at Aarhus University Hospital had at least one respiratory culture with growth of Achromobacter sp. Thirty-eight patients experienced a first-time detection of Achromobacter sp., while five patients had contracted Achromobacter sp. prior to the study period. Isolates collected prior to the study period were not included as systematic registration and storage was only implemented as of 2003. One isolate cultured only once (in 2003) was unviable when re-examined for this study (patient CF9). During 2014, 18 of 172 (10.5 %) CF patients had one or more respiratory samples that were positive for Achromobacter sp., with four patients experiencing a first-time detection ( Table 1 ). The prevalence of Achromobacter sp. at our centre increased from 6 % in 2005 to 10 % in 2009 [3] , and it has remained relatively constant thereafter. nrdA gene sequencing of isolates of Achromobacter from 42 patients showed that the most prevalent species were Achromobacter xylosoxidans, identified in 15 (36 %) patients, Achromobacter insuavis, identified in 10 (24 %) patients, Achromobacter ruhlandii, identified in eight (19 %) patients, and Achromobacter aegrifaciens, identified in two (5 %) patients.
The remaining seven CF patients carried strains of Achromobacter of seven other species or genogroups (Fig. 1) . To investigate the frequency of shared strains and putative cross-infections, PFGE was performed on the 42 isolates ( Fig. S1 , available in the online Supplementary Material). Only a single cluster of shared strains was revealed, involving seven patients carrying strains with identical pulsotypes representing A. ruhlandii (nrdA allele 27). The remaining 35 patients carried strains with unique PFGE profiles, including six isolates of nrdA allele 36 (A. xylosoxidans) and four isolates of nrdA allele 45 (A. insuavis; Table 1 ).
Partial nrdA gene sequencing differentiated Achromobacter isolates from 42 patients into 11 different species and genogroups. A similar diversity was observed in the USA (14 different Achromobacter species and genogroups from 341 CF patients) [15] , in Spain (six different species and genogroups from 14 CF patients) [16] , in the UK (12 species and genogroups from 96 CF patients) [17] and in France (11 species and genogroups from 47 CF patients) [18] . In congruence with these studies, A. xylosoxidans was the Achromobacter sp. most frequently colonising the airways of CF patients. A. insuavis was also common in the UK (12 of 96 patients), in Spain (two of 14 patients) and in France (nine of 47 patients), while it was rarer among the US patients (15 of 341 patients). In contrast, our third most prevalent species, A. ruhlandii, was only identified in three of 96 patients in the UK and none in Spain and France, but constituted the second most prevalent Achromobacter sp. in the USA [80 of 341 (23.5 %) patients]. However, patient-to-patient transmissions, which were decisive for the Danish prevalence of A. ruhlandii, were not addressed in the data from the USA.
Eighteen of 41 (43.9 %) Achromobacter-positive CF patients were chronically infected. Two patients (CF4 and CF5) were chronically infected at the beginning of the study period and were omitted from further calculations. Seven of 15 (46.7 %) patients carrying A. xylosoxidans and five of 10 (50 %) patients carrying A. insuavis were chronically infected. All eight (100 %) patients carrying strains of A. ruhlandii were chronically infected. Seven of these patients carried the same clone of A. ruhlandii, the Danish epidemic strain (DES). DES is an exceptionally transmissible clone of A. ruhlandii that has spread among patients from both Danish CF centres and has become pan-resistant [19, 20] . Four patients, CF3, CF4, CF7 and CF10, acquired DES between 2002 and 2004 and were part of a larger outbreak affecting eight patients from the Copenhagen CF centre and five patients from the CF centre in Aarhus. The patients were known to have had close social contact when participating in social activities for CF patients [3] . Patients CF16 and CF27 acquired DES during 2007 and 2011, respectively. Both were known to have had close social contact with other DES patients outside the hospital setting. Patient CF24 acquired DES in 2010, possibly as a consequence of simultaneous hospitalisation with another DES patient. This is the only registered encounter between CF24 and other DES carriers in the 12 preceding months. At the CF centre in Aarhus, patients carrying DES have been segregated for years, while segregation of all patients with Achromobacter was implemented in 2014. We found that colonisation with A. ruhlandii is associated with an increased risk of chronic infection compared with infection with other Achromobacter sp. (P=0.001). A similar association was not found for A. xylosoxidans (P=0.72), A. insuavis (P=0.44) or A. ruhlandii (P=0.12) when excluding DES. Seven out of eight CF patients colonised with A. ruhlandii carried DES, and further studies are required to determine if the increased risk of chronic infection is a characteristic of A. ruhlandii or only DES.
In summary, our study has shown that a wide diversity of Achromobacter sp. may sporadically colonise the airways of CF patients, while chronic infection is more or less limited to A. xylosoxidans, A. insuavis and A. ruhlandii. Further studies are required to elucidate possible differences in the tropism and pathogenicity of Achromobacter sp.
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